Streetbeat News

Regulatory

HUMA

Humacyte shares are trading higher after the company announced it was granted Regenerative Medicine Advanced Therapy designation by the FDA for patients with advanced peripheral artery disease.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:51 pm

TSLA

Tesla's Cybertruck owners have reported several issues including battery drainage, lack of full self-driving (FSD) software, and charging infrastructure problems. Tesla has acknowledged the feedback and promised improvements. The company is ramping up production with a goal of delivering 250,000 units annually by 2025.

Portfolio Pulse from Anan Ashraf

July 01, 2024 | 12:49 pm

SAVA

Cassava Sciences shares are experiencing volatility as the company engages with the DOJ and SEC amid ongoing investigations. An Ad Hoc Committee has been empowered for an internal investigation based on SEC findings.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:47 pm

OCTO

Eightco Holdings Inc. (NASDAQ:OCTO) has been granted continued listing on the Nasdaq Capital Market, subject to meeting certain conditions by August 23, 2024. The company is seeking shareholder approval for a 1-for-5 reverse stock split to meet the minimum bid price requirement.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:38 pm

ICCM

IceCure Medical Ltd. (NASDAQ:ICCM) has received FDA clearance for its next-generation XSense Cryoablation System with CryoProbes, a minimally-invasive technology for tumor destruction.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:33 pm

ALLO

Allogene Therapeutics has started patient screening for its pivotal Phase 2 ALPHA3 trial at several cancer centers. The trial aims to offer CAR T as a first-line treatment at community cancer centers, with enrollment expected to complete by the first half of 2026 and a potential BLA submission in 2027.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:31 pm

FOXO

FOXO Technologies has regained SEC compliance after filing its Form 10-Q for the quarter ended March 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:30 pm

NRXP

NRx Pharmaceuticals has provided a shareholder update outlining potential revenue and profitability paths for 2025. The company anticipates revenue in 2024 from HOPE Therapeutics-branded clinics and in 2025 from the sales of NRX-100 (IV Ketamine) pending FDA approval, as well as NRX-101 for suicidal bipolar depression and akathisia.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:15 pm

SAVA

Cassava Sciences is engaging with the DOJ and SEC amid ongoing investigations. The company's board has empowered an ad hoc committee for an internal investigation based on SEC findings. Dr. Hoau-Yan Wang, a former scientific advisor to Cassava, has been indicted by the DOJ for allegedly defrauding the NIH with false research data.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:07 pm

HUMA

Humacyte has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its acellular tissue-engineered vessel, which is used in treating advanced peripheral artery disease.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:01 pm